Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post-Covid future

Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business. The biotech company said it expects 10 new product approvals through 2027. But Moderna said it will also pause work on some products in its pipeline and scrap others, as it aims to "pace ourselves" in new research and development spending. The company aims to trim R&D spending to a range of $3.6 billion to $3.8 ...